Abstract:Objectives: Long-term hepatitis B virus (HBV) infection can cause recurrent inflammation in the liver, and then develop into liver fibrosis, cirrhosis, and liver cancer. The hepatic pathological change is one of the important criteria for guiding antiviral therapy in patients with chronic hepatitis B (CHB). Due to the limitations of liver biopsy, it is necessary to find valuable non-invasive indicators to evaluate the hepatic pathological changes in CHB patients and guide the antiviral therapy. This study aims to analyze the clinical characteristics of different pathological changes in CHB patients, and to explore the factors influnencing the degree of liver inflammation and fibrosis in CHB patients with normal alanine aminotransferase (ALT). Methods: This retrospective study was conducted on 310 CHB patients. Liver biopsy was performed in all these patients. The clinical data of the patients were collected. The liver biopsy pathological results were used as the gold standard to analyze the relationship between clinical indicators and liver pathological changes. Then CHB patients with normal ALT were screened, and the independent factors influencing the degree of liver inflammation and fibrosis were explored. Results: Among the 310 patients with CHB, there were 249 (80.3%) patients with significant liver inflammation [liver inflammation grade (G) ≥2] and 119 (38.4%) patients with significant liver fibrosis [liver fibrosis stage (S) ≥2]. The results of univariate analysis of total samples showed that the ALT, γ-glutamyl transferase, alkaline phosphatase, and HBV DNA were related to the significant liver pathological changes. Among the 132 CHB patients with normal ALT, the patients with liver pathology G/S≥2, G≥2, and S≥2 were 80.3% (106/132), 68.2% (90/132), and 43.2% (57/132), respectively. The results showed that the independent influencing factor of significant liver inflammation was HBV DNA>2 000 U/mL (OR=3.592, 95% CI 1.534 to 8.409), and the independent influencing factors of significant liver fibrosis were elevated alkaline phosphatase level (OR=1.022, 95% CI 1.002 to 1.043), decreased platelet count (OR=0.990, 95% CI 0.982 to 0.998), and positive in hepatitis B e antigen (HBeAg) (OR=14.845, 95% CI 4.898 to 44.995). According to the multivariate analysis, a diagnostic model for significant liver fibrosis in CHB patients with normal ALT was established, and the area under the receiver operating characteristic curve was 0.844 (95% CI 0.779 to 0.910). Conclusions: The liver pathological changes should be evaluated in combination with different clinical indicators. A considerable number of CHB patients with normal ALT still have significant liver pathological changes, which need to be identified and treated with antiviral therapy in time. Among them, HBV DNA>2 000 U/mL suggests the significant liver inflammation, and the diagnostic model for significant liver fibrosis based on alkaline phosphatase, platelet count, and HBeAg can help to evaluate the degree of liver fibrosis.

Liver Inflammation Activity in Patients with Autoimmune Hepatitis with Normal Alanine Aminotransferase and Immunoglobulin G Levels

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

Noninvasive Indicators Predict Advanced Liver Fibrosis in Autoimmune Hepatitis Patients.

Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center

Noninvasive Inflammatory Markers for Assessing Liver Fibrosis Stage in Autoimmune Hepatitis Patients

Noninvasive Indices for Monitoring Disease Course in Chinese Patients with Autoimmune Hepatitis.

Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels

Selected Cytokines Serve As Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients with Normal to Mildly Elevated Aminotransferases.

Study on liver histopathology of chronic HBV infected patients with different normal ALT values

Serum ferritin levels are associated with advanced liver fibrosis in treatment-naive autoimmune hepatitis

Expressions of Th1 and Th2 cells in Patients with Autoimmune Liver Disease (AILD) and their Correlation with the Liver Function

Presence of Liver Inflammation in Asian Patients with Chronic Hepatitis B with Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis

Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis

Alanine aminotransferase and aspartate aminotransferase levels are sensitive indicators for liver inflammation grading in HBeAg-negative chronic hepatitis B patients

Role of Quantitative Hepatitis B Core Antibody Levels in Predicting Significant Liver Inflammation in Chronic Hepatitis B Patients with Normal or Near-Normal Alanine Aminotransferase Levels.

[Study of the Correlation Between Elevated Level of T-bet Expression and Liver Damage in Peripheral Plasma Cells of Patients with Autoimmune Hepatitis].

Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B

The Imbalance Between Foxp3(+)Tregs and Th1/Th17/Th22 Cells in Patients with Newly Diagnosed Autoimmune Hepatitis